These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 37919459)

  • 1. A novel immune-related gene signature for predicting immunotherapy outcomes and survival in clear cell renal cell carcinoma.
    Gu J; Zhang X; Peng Z; Peng Z; Liao Z
    Sci Rep; 2023 Nov; 13(1):18922. PubMed ID: 37919459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional enrichment analysis of LYSET and identification of related hub gene signatures as novel biomarkers to predict prognosis and immune infiltration status of clear cell renal cell carcinoma.
    Chen Y; He J; Jin T; Zhang Y; Ou Y
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16905-16929. PubMed ID: 37740762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel necroptosis-related long noncoding RNA model for predicting clinical features, immune characteristics, and therapeutic response in clear cell renal cell carcinoma.
    Zhang L; Chen Y; Hu W; Wu B; Ye L; Wang D; Bai T
    Front Immunol; 2023; 14():1230267. PubMed ID: 37600792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune regulation and prognosis indicating ability of a newly constructed multi-genes containing signature in clear cell renal cell carcinoma.
    Gui Z; Du J; Wu N; Shen N; Yang Z; Yang H; Wang X; Zhao N; Zeng Z; Wei R; Ma W; Wang C
    BMC Cancer; 2023 Jul; 23(1):649. PubMed ID: 37438709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of an immunogenic cell death-related gene signature predicts survival and sensitivity to immunotherapy in clear cell renal carcinoma.
    Zhou S; Lu Y; Chen Y; Gan W
    Sci Rep; 2023 Mar; 13(1):4449. PubMed ID: 36932108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A promising natural killer cell-based model and a nomogram for the prognostic prediction of clear-cell renal cell carcinoma.
    Yao Q; Zhang X; Wang Y; Wang C; Chen J; Chen D
    Eur J Med Res; 2024 Jan; 29(1):73. PubMed ID: 38268058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and verification of a novel anoikis-related gene signature with prognostic significance in clear cell renal cell carcinoma.
    He Z; Gu Y; Yang H; Fu Q; Zhao M; Xie Y; Liu Y; Du W
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11661-11678. PubMed ID: 37402968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma.
    Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F
    Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel prognostic model based on immunogenomics for clear cell renal cell carcinoma.
    Wu Z; Shen Y; Fan D; Liu J; Chen D; Wang K; Xu X
    Int Immunopharmacol; 2021 Jan; 90():107119. PubMed ID: 33243605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A radiogenomics biomarker based on immunological heterogeneity for non-invasive prognosis of renal clear cell carcinoma.
    Gao J; Ye F; Han F; Jiang H; Zhang J
    Front Immunol; 2022; 13():956679. PubMed ID: 36177018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and validation of a hypoxia-related prognostic signature in clear cell renal cell carcinoma patients.
    Li Z; Du G; Zhao R; Yang W; Li C; Huang J; Wen Z; Li H; Zhang B
    Medicine (Baltimore); 2021 Oct; 100(39):e27374. PubMed ID: 34596153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An immune scores-based nomogram for predicting overall survival in patients with clear cell renal cell carcinoma.
    Wu Z; Ouyang C; Peng L
    Medicine (Baltimore); 2020 Aug; 99(34):e21693. PubMed ID: 32846785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of an Immune Prognostic Model for Clear Cell Renal Cell Carcinoma Based on Tumor Microenvironment.
    Wang M; Song Q; Song Z; Xie Y
    Horm Metab Res; 2023 Jun; 55(6):402-412. PubMed ID: 37192644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of CCNB2 and a novel lncRNAs-related risk model predict prognosis in clear cell renal cell carcinoma.
    Ren C; Wang Q; Xu Z; Pan Y; Wang S; Liu X
    J Cancer Res Clin Oncol; 2024 Feb; 150(2):64. PubMed ID: 38300330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction of the metabolic reprogramming-associated gene signature for clear cell renal cell carcinoma prognosis prediction.
    Tai R; Leng J; Li W; Wu Y; Yang J
    BMC Urol; 2023 Sep; 23(1):147. PubMed ID: 37715154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Notch signaling-related lncRNA signature for predicting prognosis and therapeutic response in clear cell renal cell carcinoma.
    Zhang L; Li Y; Cai B; Chen J; Zhao K; Li M; Lang J; Wang K; Pan S; Zhu K
    Sci Rep; 2023 Nov; 13(1):21141. PubMed ID: 38036719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and validation of a ferroptosis-related lncRNA signature to robustly predict the prognosis, immune microenvironment, and immunotherapy efficiency in patients with clear cell renal cell carcinoma.
    Ju L; Shi Y; Liu G
    PeerJ; 2022; 10():e14506. PubMed ID: 36570012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N6‑methyladenosine RNA methylation regulators participate in malignant progression and have prognostic value in clear cell renal cell carcinoma.
    Zheng Z; Mao S; Guo Y; Zhang W; Liu J; Li C; Yao X
    Oncol Rep; 2020 May; 43(5):1591-1605. PubMed ID: 32323803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction of a 12-Gene Prognostic Risk Model and Tumor Immune Microenvironment Analysis Based on the Clear Cell Renal Cell Carcinoma Model.
    Wang S; Yu Z; Cao Y; Du P; Ma J; Ji Y; Yang X; Zhao Q; Hong B; Yang Y; Hai Y; Li J; Mao Y; Wu S
    Cancer Control; 2024; 31():10732748241272713. PubMed ID: 39115042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.